LeonaBio, Inc. (LONA) stock
Close on Nov 17, 2026Market cap $26.00MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $26.00M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.77
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$141.46M
- EPS, diluted
- -$19.72
- Book value per share
- $1.42
- Diluted shares
- 24M
Trading
- Next earnings
- Q3 FY2026, expected soon
- Previous close
- $3.23
- Open
- $3.17
- Day's range
- $2.75 – $3.32
- Volume
- 24,683
- Average volume (20 days)
- 60,194
- 52-week range
- $2.21 – $14.21
- RSI (14 days)
- 22.4
- Volatility (1 year)
- 120.6%
- Relative volume
- 0.16×
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 17, 2026. The S&P 500 is measured by the SPY fund.
| Period | LONA | S&P 500 | Difference | LONA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -46.9% | -4.0% | −42.9 pts | ||
| 3 months | -64.2% | -5.0% | −59.2 pts | ||
| Year to date | -63.5% | +8.2% | −71.8 pts | ||
| 1 year | -40.0% | +11.2% | −51.2 pts | ||
| 3 years | -83.7% | +68.5% | −152.1 pts | -45.3% | +19.0% |
| 5 years | -98.2% | +67.3% | −165.5 pts | -55.1% | +10.8% |
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases LeonaBio filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Update
About LeonaBio
Biological Products, (No Diagnostic Substances)
Athira Pharma is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for diseases with substantial unmet medical needs, primarily targeting neurological disorders and treatment-resistant oncology. Its lead oncology candidate is lasofoxifene, an orally bioavailable selective estrogen receptor modulator in Phase 3 clinical evaluation for patients with ESR1-mutated metastatic breast cancer. In neurology, the company develops ATH-1105, an orally administered small-molecule positive modulator of the hepatocyte growth factor system being prepared for Phase 2 clinical trials in individuals with amyotrophic lateral sclerosis. The company additionally explores early-stage pipeline assets, such as ATH-1020, to improve neuronal function. Target patient populations consist of individuals living with neurodegenerative conditions and advanced breast cancer.
Company profile, executives and historyLeonaBio stock: common questions
What is LeonaBio's stock price?
LONA closed at $2.76 on Nov 17, 2026, down 14.55% on the day. Over the past 52 weeks it traded between $2.21 and $14.21.
What is LeonaBio's market cap?
LeonaBio was worth $26.00M at the close on Nov 17, 2026: the share price times the diluted shares outstanding.
What is LONA's P/E ratio?
LeonaBio lost money over the twelve months to Jun 30, 2026 (diluted EPS -$19.72), so it has no meaningful P/E ratio.
Does LeonaBio pay a dividend?
No. LeonaBio has not paid a cash dividend over the last twelve months.
When does LeonaBio report earnings next?
LeonaBio's Q3 FY2026 results are due soon; the company has not yet filed them with the SEC.
How has LONA stock performed over the past year?
Including dividends, LONA returned -40.0% over the past year, against +11.2% for the S&P 500.
Who are LeonaBio's competitors?
Companies most similar to LeonaBio by business, industry and size include NMRA, AVXL, EIKN, CCCC, CGTX.
See a number that looks wrong?